Diletta Di Mitri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7001687/publications.pdf

Version: 2024-02-01

20 papers 3,514 citations

471509 17 h-index 752698 20 g-index

20 all docs

20 docs citations

20 times ranked

6685 citing authors

#	Article	IF	CITATIONS
1	Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer. Journal of Experimental Medicine, 2022, 219, .	8.5	53
2	Neutrophil diversity and plasticity in tumour progression and therapy. Nature Reviews Cancer, 2020, 20, 485-503.	28.4	548
3	Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. Cell Reports, 2019, 28, 2156-2168.e5.	6.4	129
4	Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics, 2018, 50, 219-228.	21.4	139
5	IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature, 2018, 559, 363-369.	27.8	258
6	Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer. Trends in Cell Biology, 2016, 26, 215-226.	7.9	71
7	The p38 mitogenâ€activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis. Immunology, 2015, 146, 251-263.	4.4	24
8	Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy. Clinical Cancer Research, 2015, 21, 3108-3112.	7.0	39
9	A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nature Communications, 2015, 6, 7227.	12.8	37
10	Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors. Oncolmmunology, 2015, 4, e988473.	4.6	7
11	Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors. Oncolmmunology, 2015, 4, e994380.	4.6	21
12	Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity. Cell Reports, 2014, 9, 75-89.	6.4	313
13	CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. Immunology Letters, 2014, 158, 134-142.	2.5	36
14	Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature, 2014, 515, 134-137.	27.8	284
15	Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4+â€fCD45RA+â€fCD27â°' T cells: the potential involvement of interleukin-7 in this process. Immunology, 2011, 132, 326-339.	4.4	85
16	Reversible Senescence in Human CD4+CD45RA+CD27â^' Memory T Cells. Journal of Immunology, 2011, 187, 2093-2100.	0.8	193
17	T Regulatory Cells Are Markers of Disease Activity in Multiple Sclerosis Patients. PLoS ONE, 2011, 6, e21386.	2.5	64
18	CD49d provides access to "untouched―human Foxp3+ Treg free of contaminating effector cells. Blood, 2009, 113, 827-836.	1.4	132

#	Article	IF	CITATIONS
19	Efficacy of a Nanocochleate-Encapsulated 3,5-Diaryl-s-Triazole Derivative in a Murine Model of Graft-Versus-Host Disease. Transplantation, 2008, 86, 171-175.	1.0	7
20	Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood, 2007, 110, 1225-1232.	1.4	1,074